Ser485
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser485  -  TELO2 (human)

Site Information
PQAQLAGsDsDLDsD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27530803

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
glioblastoma multiforme ( 1 ) , glioma ( 1 )
Relevant cell line - cell type - tissue:
COS7 (fibroblast) ( 1 ) , HEK293T (epithelial) ( 1 ) , liver ( 1 ) , T98G (glial) ( 1 )

Upstream Regulation
Putative in vivo kinases:
CK2A1 (human) ( 1 )
Kinases, in vitro:
CK2A1 (human) ( 1 )
Treatments:
fasting ( 1 ) , serum_withdrawal ( 1 ) , siRNA ( 1 ) , sorbitol ( 1 )

Downstream Regulation
Effects of modification on TELO2:
intracellular localization ( 1 ) , molecular association, regulation ( 1 ) , protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 )
Induce interaction with:
FBXO9 (human) ( 1 )

References 

1

Fernández-Sáiz V, et al. (2013) SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nat Cell Biol 15, 72-81
23263282   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.